{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".5654","upperLimit":".8401","value":"0.7174"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"This will be estimated by the number of patients with an objective status of stringent complete responses, complete response, very good partial response, or partial response at the day 100 post ASCT assessment divided by the total number of evaluable patients. Response assessment will be in comparison to values obtained at the disease assessment at the time registration. Exact binomial 95% confidence intervals for the true overall response rate at day 100 post ASCT will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, and on days 1 and 15 of cycles 3-4. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after completion of daratumumab cycle 2 or 4, patients undergo ASCT. Within 14 days after completion of day 100 visit post-SCT, patients receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Daratumumab, ASCT, Lenalidomide)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}